Caignard A, Pelletier H, Martin F
INSERM U.252, Faculty of Medicine, Dijon, France.
Int J Cancer. 1988 Dec 15;42(6):883-6. doi: 10.1002/ijc.2910420616.
Two cell clones, K12/TRb (PROb) and K12/TSb (REGb), have been isolated from the same serially transplantable tumor, DHD, established from a colon carcinoma chemically induced in the rat. Inoculation of REGb cells gives a tumor which regresses within 4 to 8 weeks and generates immune protection against subsequent injection of the progressive tumor cells, PROb. Inoculation of PROb cells gives a progressive tumor and generates tolerance allowing progressive growth of contralaterally injected REGb cells. Inoculation of REGb cells fully protects the host against growth of a DHD tumor graft, the tumor from which REGb and PROb cells were originally obtained. On the other hand, inoculation of REGb cells does not confer any protection against growth of 4 other syngeneic tumor grafts, DHA, DHB, DHC and DHE. These tumors were obtained from other colonic tumors induced as DHD by 1.2 dimethylhydrazine (DMH). Progressive growth of the tumor induced by inoculation of REGb cells is observed in animals bearing a contralateral DHD tumor, but not in animals bearing tumor from other transplantable lines, DHA, DHB, DHC and DHE. Our results show that immune enhancement of a regressive tumor and the immune protection that it confers constitute specific responses to a tumor-specific transplantation antigen present on a single transplantable colon tumor.
从大鼠化学诱导的结肠癌建立的同一可连续移植肿瘤DHD中分离出了两个细胞克隆，即K12/TRb（PROb）和K12/TSb（REGb）。接种REGb细胞会产生一个在4至8周内消退的肿瘤，并产生针对后续注射的进行性肿瘤细胞PROb的免疫保护。接种PROb细胞会产生一个进行性肿瘤，并产生耐受性，允许对侧注射的REGb细胞进行性生长。接种REGb细胞可使宿主完全免受DHD肿瘤移植物的生长影响，REGb和PROb细胞最初就是从该肿瘤中获得的。另一方面，接种REGb细胞对其他4种同基因肿瘤移植物DHA、DHB、DHC和DHE的生长没有提供任何保护。这些肿瘤是从由1,2-二甲基肼（DMH）诱导的与DHD相同的其他结肠肿瘤中获得的。在对侧患有DHD肿瘤的动物中观察到接种REGb细胞诱导的肿瘤进行性生长，但在患有其他可移植系肿瘤DHA、DHB、DHC和DHE的动物中未观察到。我们的结果表明，消退性肿瘤的免疫增强及其赋予的免疫保护构成了对存在于单个可移植结肠肿瘤上的肿瘤特异性移植抗原的特异性反应。
